Services
Drug Discovery
Drug Metabolism Platform
Toxicity Screening Platform
Non-Clinical
In yitro Biological Evaluation Platform
Pharmacology and Efficacy Study Platform
Drug Metabolism Platform
Toxicity Screening Platform
JOINN (China)
Founded in 1995, JOINN Laboratories (stock codes: 603127.SH / 6127.HK) is a leading global Contract Research Organization (CRO) with operations in major cities across China - including Beijing, Suzhou, and Guangzhou, as well as in the United States, with facilities in San Francisco and Boston. JOINN is dedicated to accelerating the research and development of innovative therapies by delivering high-quality, globally aligned services. Our qualifications include CNAS/ILAC accreditation, multi-country GLP compliance (China, the United States, the OECD, Japan, and South Korea), and AAALAC accreditation, ensuring the highest international standards of quality and reliability.
JOINN (California)
Our laboratory is conveniently located in the San Francisco Bay area and features nearly 60,000 square feet of dedicated rodent vivarium space for mouse and rat models alongside advanced cell culture laboratory with robust in vitro capabilities, supporting a board range of preclinical research services.
Core Advantages
News Updates
MORE
Meet the Era, Witness Innovation Power | JOINN Invites You to CPIC 2026, to Explore a New Journey of Hot-Topic Pharmaceutical Nonclinical Evaluation
July 22–24, 2026 will witness the grand opening of the inaugural China Pharmaceutical Innovation Conference (CPIC 2026) at the National Exhibition and Convention Center (Shanghai). Benchmarked against
JOINN (Suzhou) Successfully Passes FDA Inspection
In May 2026, JOINN (Suzhou) completed an on-site audit conducted by the U.S. Food and Drug Administration (FDA). The quality management system fully satisfies FDA GLP requirements, earning a successfu
Exhibition News | Joinn Laboratories Invites You to BioQual 2026 to Jointly Explore the Path of Full-Cycle Quality Innovation in Biopharmaceuticals
The 2nd BioQual Conference on Full-Cycle Quality Innovation and Compliance of Biopharmaceuticals will be held in Suzhou on May 28-29, 2026.With the core theme of "New Quality Paradigm: From Compl
